Antiplatelet agent vs control: Cardiovascular mortality
It is very uncertain whether antiplatelet agents changes cardiovascular death compared with control (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Antiplatelet agents vs control Cardiovascular death · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients) It is very uncertain whether antiplatelet agents changes cardiovascular death compared with control (very low certainty). Antiplatelet agents for chronic kidney disease (2022) · Cochrane Headline outcomes only | RR 0.87 [0.65, 1.15] | 21 studies · 9606 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antiplatelet agents for chronic kidney disease 2022 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.